nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT01514045,The Gastric Cancer Foundation: A Gastric Cancer Registry,,Recruiting,Observational,Gastric Cancer,,,Stanford University,,500,2011-04-05,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT01514045
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02417740,Natural History of Noncirrhotic Portal Hypertension,,Recruiting,Observational,Cystic Fibrosis; Immunologic Deficiency Syndrome; Turner Syndrome; Congenital Hepatic Fibrosis; Idiopathic Non-Cirrhotic Portal Hypertension,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,400,2015-07-27,2029-09-04,United States,No,https://clinicaltrials.gov/study/NCT02417740
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT03551951,"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",,Recruiting,Observational,Non Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Hepatocellular Cancer; Colorectal Cancer,"Test for circulating tumor cells, DNA alterations",,University of Missouri-Columbia,Harry S. Truman Memorial Veterans' Hospital,320,2016-07-01,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT03551951
NCT03607890,Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor,Phase 2,Recruiting,Interventional,Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy; MSI-H Tumors,Nivolumab; Relatlimab; Nivolumab; Relatlimab; Nivolumab; Relatlimab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Bristol-Myers Squibb; National Cancer Institute (NCI),42,2018-11-16,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT03607890
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03769415,HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer,Not Applicable,Recruiting,Interventional,Breast Cancer,Intrinsic Subtyping of Primary Breast Cancer,,UNC Lineberger Comprehensive Cancer Center,"Veracyte, Inc.; Breast Cancer Research Foundation",500,2018-11-06,2030-12-15,United States,No,https://clinicaltrials.gov/study/NCT03769415
NCT03935893,A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers,Phase 2,Recruiting,Interventional,Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Sarcoma; Mesothelioma; Neuroendocrine Tumors; Squamous Cell Cancer; Merkel Cell Carcinoma; Mismatch Repair Deficiency; Microsatellite Instability,Tumor Infiltrating Lymphocytes (TIL); Fludarabine + Cyclophosphamide combination,,Udai Kammula,,240,2019-12-03,2038-06-30,United States,No,https://clinicaltrials.gov/study/NCT03935893
NCT04107077,A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases,Phase 2,Recruiting,Interventional,Gastric Cancer; Peritoneal Carcinomatosis,Cisplatin; Mitomycin,,University of Chicago,,21,2025-09-09,2026-06-01,United States,No,https://clinicaltrials.gov/study/NCT04107077
NCT04114136,A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies,Phase 2,Recruiting,Interventional,Melanoma; NSCLC; Hepatocellular Carcinoma; Urothelial Cancer; Gastric Adenocarcinoma; HNSCC; Esophageal Adenocarcinoma; Microsatellite Instability-High Solid Malignant Tumor,Nivolumab or Pembrolizumab (dependent upon approved indication); Metformin; Rosiglitazone,,Dan Zandberg,,72,2020-09-14,2032-04-30,United States,No,https://clinicaltrials.gov/study/NCT04114136
NCT04191551,The GAstric Precancerous Conditions Study,,Recruiting,Observational,Gastric Cancer; Intestinal Metaplasia of Gastric Mucosa; Helicobacter Pylori Infection; Atrophic Gastritis,,,Stanford University,,600,2018-07-30,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT04191551
NCT04221893,Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI),Not Applicable,Recruiting,Interventional,Stage IV Esophageal Adenocarcinoma; Stage IV Esophageal Squamous Cell Carcinoma; Stage IV Gastric Cancer; Stage IV Adenocarcinoma of the Gastroesophageal Junction; Stage IVA Esophageal Adenocarcinoma; Stage IVA Esophageal Squamous Cell Carcinoma; Stage IVA Gastric Cancer; Stage IVA Adenocarcinoma of the Gastroesophageal Junction; Stage IVB Esophageal Adenocarcinoma; Stage IVB Esophageal Squamous Cell Carcinoma; Stage IVB Gastric Cancer; Stage IVB Gastroesophageal Junction Adenocarcinoma; Metastatic Anal Canal Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Digestive System Neoplasm; Metastatic Small Intestinal Carcinoma; Pancreatobiliary Carcinoma; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage IV Anal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Radiation Therapy (RT),,"University of California, San Francisco",Varian Medical Systems,28,2020-08-07,2028-04-30,United States,No,https://clinicaltrials.gov/study/NCT04221893
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04383262,"A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux",Phase 2,Not yet recruiting,Interventional,Laryngopharyngeal Reflux,Fosamprenavir Calcium; Placebo,,Medical College of Wisconsin,,104,2026-03-01,2027-10-01,United States,No,https://clinicaltrials.gov/study/NCT04383262
NCT04553770,"A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting",Phase 2,Recruiting,Interventional,Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Anastrozole; Therapeutic Conventional Surgery; Trastuzumab Deruxtecan,,Jonsson Comprehensive Cancer Center,"Translational Research in Oncology-U.S; Daiichi Sankyo Co., Ltd.",88,2020-10-09,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04553770
NCT04573231,"Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT",Phase 2,Recruiting,Interventional,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,18F-DCFPyL,,"University of Wisconsin, Madison",,13,2021-05-24,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT04573231
NCT04609592,"Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",Phase 1,Recruiting,Interventional,Gastroenteropancreatic Neuroendocrine Tumor,Lutathera; Gallium 68 Dotatate; Computed Tomography (CT); Magnetic Resonance Imaging (MRI); PET/CT,,Stanford University,Novartis Pharmaceuticals,10,2021-03-17,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04609592
NCT04762953,Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP),Phase 2,Recruiting,Interventional,Gastric Cancer; Peritoneal Carcinomatosis; Gastroesophageal Junction Adenocarcinoma,Paclitaxel; Paclitaxel; Leucovorin; Fluorouracil,,"University of California, Irvine",,40,2021-02-18,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT04762953
NCT04777994,A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors,Phase 1,Recruiting,Interventional,Advanced Solid Tumor Cancer,ABBV-CLS-484; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI); Programmed Cell Death-1 (PD-1) Inhibitor,,Calico Life Sciences LLC,,248,2021-03-09,2026-10-05,France; Israel; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04777994
NCT04787042,"A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Cancer; Solid Tumor; Melanoma; Renal Cell Carcinoma; Triple-negative Breast Cancer; Non Small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Carcinoma; MSI-High,ST-067; Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]; pembrolizumab,,"Simcha IL-18, Inc.",Merck Sharp & Dohme LLC,316,2021-08-06,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04787042
NCT04862663,"A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)",Phase 3,Recruiting,Interventional,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib; Fulvestrant; Palbociclib; Ribociclib; Abemaciclib,,AstraZeneca,,895,2021-05-10,2029-08-14,Argentina; Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; India; Italy; Japan; Malaysia; Poland; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT04862663
NCT04872166,"An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 Alone and in Combination With Fulvestrant in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Breast Cancer,BTX-A51,,Edgewood Oncology Inc.,,112,2021-06-07,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT04872166
NCT04899908,"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",Phase 2,Recruiting,Interventional,Brain Cancer; Brain Metastases; Melanoma; Lung Cancer; Breast Cancer; HER2-positive Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; SRS; SRT; Whole Brain Radiation; Stereotactic Radiation; AGuIX; Nanoparticle; Cystic; Brain Tumor,Stereotactic Radiation; AGuIX gadolinium-based nanoparticles; Placebo,,Dana-Farber Cancer Institute,NH TherAguix SAS,134,2021-09-15,2026-02-05,United States,No,https://clinicaltrials.gov/study/NCT04899908
NCT04995003,Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0),Phase 1,Recruiting,Interventional,Sarcoma; HER-2 Protein Overexpression; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma; Synovial Sarcoma; Soft Tissue Sarcoma; Undifferentiated Sarcoma,T cells or CAR T cells; Pembrolizumab Injectable Product; Nivolumab Injectable Product,,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation; National Cancer Institute (NCI)",25,2021-12-07,2040-12-31,United States,No,https://clinicaltrials.gov/study/NCT04995003
NCT05038098,"Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial",Phase 1,Not yet recruiting,Interventional,Gastric Adenocarcinoma,Gastrectomy; Indocyanine Green; Iron Conjugated Polymers in Saline Suspension,,M.D. Anderson Cancer Center,,20,2026-03-31,2027-02-02,United States,No,https://clinicaltrials.gov/study/NCT05038098
NCT05041153,A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma,Early Phase 1,Recruiting,Interventional,Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma,Lenvatinib; Pembrolizumab,,M.D. Anderson Cancer Center,,15,2022-02-14,2025-12-30,United States,No,https://clinicaltrials.gov/study/NCT05041153
NCT05083754,"A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma",Phase 1,Recruiting,Interventional,Glioblastoma Multiforme,Retifanlimab; Temozolomide; Radiation Therapy,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Incyte Corporation,50,2022-08-31,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05083754
NCT05086692,"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer; Viral Cancer; Cervical Cancers; Endometrial Cancer",MDNA11; Pembrolizumab (KEYTRUDA®),,"Medicenna Therapeutics, Inc.",Merck Sharp & Dohme LLC,115,2021-08-27,2026-12-30,Australia; Canada; Ireland; Portugal; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05086692
NCT05172245,Phase 1/1b Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer,Phase 1,Recruiting,Interventional,Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Nasal Cavity Squamous Cell Carcinoma; Locally Advanced Oral Cavity Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma; Locally Advanced Paranasal Sinus Squamous Cell Carcinoma; Locally Advanced Sinonasal Squamous Cell Carcinoma; Maxillary Sinus Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Sinonasal Cancer AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Sinonasal Cancer AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Sinonasal Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography; Ipatasertib; Magnetic Resonance Imaging; Positron Emission Tomography; Radiation Therapy,,National Cancer Institute (NCI),,46,2022-09-19,2026-06-01,Canada; United States,No,https://clinicaltrials.gov/study/NCT05172245
NCT05176665,"Phase Ib/II, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers",Phase 1/Phase 2,Recruiting,Interventional,Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor,EMB-01,,"Shanghai EpimAb Biotherapeutics Co., Ltd.","Labcorp Corporation of America Holdings, Inc",152,2021-10-21,2025-12-31,China; United States,No,https://clinicaltrials.gov/study/NCT05176665
NCT05187182,Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer,Phase 1,Recruiting,Interventional,Gastric Cancer; Esophageal Cancer; Stomach Cancer; Esophagus Cancer; Gastroesophageal Junction Cancer,CA-4948; Nivolumab; Pembrolizumab; Trastuzumab; mFOLFOX7,,Washington University School of Medicine,"Curis, Inc.; The Foundation for Barnes-Jewish Hospital",42,2023-06-02,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05187182
NCT05205343,Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers,,Recruiting,Observational,Gastrostomy; Gastric; GastroEsophageal Cancer,Standard of Care; Control Group,,M.D. Anderson Cancer Center,,20,2022-05-11,2026-05-31,Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05205343
NCT05230810,"This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.",Phase 1/Phase 2,Recruiting,Interventional,HER2-positive Metastatic Breast Cancer,Alpelisib; Tucatinib; Fulvestrant,,"Criterium, Inc.",Novartis; Seagen Inc.,40,2022-08-25,2025-06-30,United States,No,https://clinicaltrials.gov/study/NCT05230810
NCT05232916,"A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)",Phase 3,Recruiting,Interventional,Breast Cancer,Placebo; GLSI-100,,"Greenwich LifeSciences, Inc.",,750,2022-08-11,2026-12-05,France; Germany; Ireland; Italy; Poland; Romania; Spain; United States,No,https://clinicaltrials.gov/study/NCT05232916
NCT05239546,"Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers",Phase 2,Recruiting,Interventional,Colon Cancer; dMMR Colorectal Cancer,Dostarlimab,,University of Iowa,,25,2023-03-24,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT05239546
NCT05267626,"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer,AU-007; Aldesleukin; Avelumab; Nivolumab,,"Aulos Bioscience, Inc.",,159,2022-04-04,2026-06-12,Australia; United States,No,https://clinicaltrials.gov/study/NCT05267626
NCT05273307,"Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy: A Double-blinded, Placebo-controlled, Randomized Phase III Trial",Phase 3,Recruiting,Interventional,Head and Neck Cancer; Taste Dysfunction,Miraculin; Miracle Fruit Placebo Cube,,"University of California, San Francisco",Miracle Fruit Farm; Mount Zion Health Fund,40,2022-03-04,2026-09-30,United States,No,https://clinicaltrials.gov/study/NCT05273307
NCT05274048,A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients,Phase 1,Recruiting,Interventional,Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation,Neratinib Pill; Fam-Trastuzumab Deruxtecan-Nxki (TDxD),,Fox Chase Cancer Center,"National Comprehensive Cancer Network; Puma Biotechnology, Inc.",18,2022-06-24,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT05274048
NCT05313243,Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma,Phase 2,Recruiting,Interventional,T-Cell Lymphoma,Brentuximab vedotin; Pembrolizumab,,Yale University,Merck Sharp & Dohme LLC,32,2023-07-10,2028-07-30,United States,No,https://clinicaltrials.gov/study/NCT05313243
NCT05366881,"cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse",,Recruiting,Observational,Brain Cancer; Breast Cancer; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Esophageal Cancer; Stomach Cancer; Head and Neck Cancer; Hepatobiliary Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer; Sarcoma; Thyroid Cancer,,,"Adela, Inc",,7000,2022-05-03,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05366881
NCT05386108,"An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases,Elacestrant; Abemaciclib,,"Stemline Therapeutics, Inc.",,73,2022-08-31,2026-12-05,Belgium; France; Germany; Greece; Italy; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05386108
NCT05417594,"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies,AZD9574; Temozolomide (TMZ); [11C]AZ1419 3391; Trastuzumab Deruxtecan (T-DXd); Datopotamab Deruxtecan (Dato-DXd),,AstraZeneca,,695,2022-06-24,2027-08-11,Australia; Germany; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05417594
NCT05430035,Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma,Early Phase 1,Recruiting,Interventional,Gallbladder Adenocarcinoma,HIPEC,,West Virginia University,,10,2022-06-23,2029-07-05,United States,No,https://clinicaltrials.gov/study/NCT05430035
NCT05455619,"Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)",Phase 1/Phase 2,Recruiting,Interventional,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Evexomostat,,"SynDevRx, Inc.",,52,2022-08-26,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05455619
NCT05504707,"Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer; HER2-negative Breast Cancer,HER2 - primed Dendritic cells; HER3 - primed Dendritic cells,,H. Lee Moffitt Cancer Center and Research Institute,The Shulas' Foundation,30,2022-08-26,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05504707
NCT05520099,Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02),,Recruiting,Observational,Immunotherapy; Cancer; Bladder Cancer; Urothelial Carcinoma Bladder; Kidney Cancer; Clear Cell Renal Cell Cancer (ccRCC); Colorectal Cancer; MSI-H Colorectal Cancer; DMMR Colorectal Cancer; Head and Neck Cancer (H&N); Squamous Cell Carcinoma Head and Neck Cancer (HNSCC); Liver Cancer; Hepatocellular Carcinoma (HCC); Lung Cancer (NSCLC); NSCLC (Non-small Cell Lung Cancer); Skin Cancer; Cutaneous Melanoma; Endometrial Cancer; Solid Tumor Cancer,"Core Needle Biopsy, Forceps Biopsy, Punch Biopsy",,Elephas,,416,2023-06-26,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05520099
NCT05544019,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies",Phase 1,Recruiting,Interventional,"Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma",SGR-1505,,"Schrödinger, Inc.",,52,2023-04-10,2026-03-05,France; Italy; Moldova; Poland; Romania; Spain; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05544019
NCT05544929,"A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers",Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",KFA115; pembrolizumab,,Novartis Pharmaceuticals,,180,2022-10-26,2027-09-01,Canada; China; France; Germany; Hong Kong; Italy; Japan; Singapore; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05544929
NCT05546268,A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma,Phase 1/Phase 2,Recruiting,Interventional,"NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer",Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359; Oral MRT-2359,,"Monte Rosa Therapeutics, Inc",,174,2022-10-12,2027-11-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT05546268
NCT05579366,Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Rina-S; Carboplatin; Bevacizumab; Pembrolizumab,,Genmab,,764,2022-12-07,2027-10-05,China; Japan; United States,No,https://clinicaltrials.gov/study/NCT05579366
NCT05592626,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm",STAR0602,,"Marengo Therapeutics, Inc.",,365,2023-01-04,2026-10-05,Canada; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT05592626
NCT05608252,A Single Arm Phase 1/2 Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer,Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,VS-6766; Abemaciclib; Fulvestrant,,Adrienne G. Waks,"Verastem, Inc.; Eli Lilly and Company",63,2023-02-23,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05608252
NCT05696626,"An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",Phase 3,Recruiting,Interventional,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib,,Sermonix Pharmaceuticals Inc.,,500,2023-10-31,2028-04-05,Australia; Belgium; Canada; China; France; Germany; Israel; Italy; Poland; Romania; Singapore; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05696626
NCT05709574,"An Open-Label, Phase II Single-Arm, Window Trial of Tadalafil Effect + Chemotherapy in Patients With Resectable Gastric/GEJ Adenocarcinoma",Phase 2,Recruiting,Interventional,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,Tadalafil 20 MG,,University of Arizona,,10,2023-04-20,2026-05-31,United States,No,https://clinicaltrials.gov/study/NCT05709574
NCT05736367,Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer,Not Applicable,Recruiting,Interventional,Breast Cancer,U-13C-glucose,,"Rutgers, The State University of New Jersey",Ludwig Institute for Cancer Research,16,2024-11-15,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05736367
NCT05748834,Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer,Phase 2,Recruiting,Interventional,Breast Cancer,Tucatinib; Doxil,,"SCRI Development Innovations, LLC",Seagen Inc.; Pfizer,36,2023-07-24,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT05748834
NCT05753306,A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial,Phase 2,Recruiting,Interventional,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum,Cisplatin; Computed Tomography; Gastrectomy; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Paclitaxel; Hyperthermic Intraperitoneal Chemotherapy,,Mayo Clinic,,40,2023-04-20,2028-03-31,United States,No,https://clinicaltrials.gov/study/NCT05753306
NCT05826964,"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase 2 Randomized, Open-Label Study",Phase 2,Recruiting,Interventional,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i; SERD+CDK4/6i; mTOR inhibitor + AI; mTOR inhibitor + SERD; mTOR inhibitor + Selective estrogen receptor modulator; PI3K inhibitor + SERD; PI3K inhibitor + AI; Chemotherapy; Oral SERD; PARPi; AKT inhibitor; Step 3 Arm 2,,University of Miami,,500,2023-06-12,2029-07-31,United States,No,https://clinicaltrials.gov/study/NCT05826964
NCT05838768,"An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors.",Phase 1,Recruiting,Interventional,"MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers",HRO761; pembrolizumab; irinotecan,,Novartis Pharmaceuticals,,327,2023-06-27,2029-05-30,Belgium; China; France; Germany; Israel; Italy; Japan; Norway; Singapore; South Korea; Spain; Sweden; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05838768
NCT05855200,"A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer",Phase 3,Recruiting,Interventional,"Colonic Neoplasms; Neoplasms, Colon",Dostarlimab; CAPEOX; FOLFOX,,GlaxoSmithKline,,811,2023-08-01,2031-03-27,Argentina; Australia; Belgium; Brazil; Canada; China; Estonia; Finland; France; Germany; Greece; Italy; Japan; Mexico; Netherlands; Norway; Panama; Portugal; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05855200
NCT05894239,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",Phase 3,Recruiting,Interventional,Metastatic Breast Cancer,Inavolisib; Phesgo; Placebo; Taxane-based Chemotherapy; Optional Endocrine Therapy of Investigator's Choice,,Hoffmann-La Roche,,230,2023-09-08,2032-12-28,Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Finland; France; Germany; Hong Kong; India; Italy; Jordan; Kenya; Mexico; Oman; Poland; Singapore; South Africa; South Korea; Spain; Taiwan; Tunisia; Turkey (Türkiye); Uganda; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05894239
NCT05919264,A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,FOG-001; mFOLFOX-6; Nivolumab; Trifluridine/tipiracil; Bevacizumab,,"Parabilis Medicines, Inc.",,575,2023-05-23,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT05919264
NCT05950945,"A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)",Phase 3,Recruiting,Interventional,Breast Cancer,Trastuzumab Deruxtecan,,Daiichi Sankyo,AstraZeneca,250,2023-12-30,2027-10-01,Australia; Belgium; Brazil; China; Ireland; Italy; Netherlands; Portugal; Spain; United States,No,https://clinicaltrials.gov/study/NCT05950945
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT05986279,Improving Psychological and Vestibular Health Using a Novel Intervention: The Making Informed Decisions in Gaze and Postural Stability (MINDGAPS) System,Not Applicable,Recruiting,Interventional,Vestibular Hypofunction,Rehab,,University of Montana,"United States Naval Medical Center, San Diego; Congressionally Directed Medical Research Programs",500,2023-08-30,2027-09-29,United States,No,https://clinicaltrials.gov/study/NCT05986279
NCT05986604,"NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment",Not Applicable,Recruiting,Interventional,Sleep Disorder; Circadian Dysregulation; Memory Impairment,Memory Support Intervention; Transdiagnostic Intervention for Sleep and Circadian Dysfunction,,"University of California, Berkeley",,178,2024-01-04,2028-07-28,United States,No,https://clinicaltrials.gov/study/NCT05986604
NCT05997056,"A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors",Phase 2,Recruiting,Interventional,Neuroendocrine Tumors; NET; Pancreatic Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Tumor; Pulmonary Neuroendocrine Tumor,nab-sirolimus,,"Aadi Bioscience, Inc.",,21,2023-11-07,2025-12-08,United States,No,https://clinicaltrials.gov/study/NCT05997056
NCT06006923,Randomized Trial of Regorafenib in Combination With Pembrolizumab or Pembrolizumab Monotherapy With an Efficacy Lead-in of Regorafenib and Pembrolizumab for Patients With MSI-H Colorectal Cancer,Phase 2,Recruiting,Interventional,MSI-H Colorectal Cancer,Regorafenib; Pembrolizumab,,Anwaar Saeed,Bayer,154,2024-06-26,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT06006923
NCT06016738,"A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)",Phase 3,Recruiting,Interventional,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Palazestrant; Fulvestrant; Anastrozole; Letrozole; Exemestane,,"Olema Pharmaceuticals, Inc.",,510,2023-11-16,2027-09-30,Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czechia; France; Germany; Hong Kong; Hungary; Italy; Malaysia; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Romania; South Korea; Spain; Taiwan; Thailand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06016738
NCT06037837,Generalized Robotic Skills Assessment Using Machine Learning-Based Analysis Across Multiple Surgical Specialties,,Enrolling by invitation,Observational,Surgery,Robotic Surgery,,Memorial Sloan Kettering Cancer Center,,1000,2023-08-24,2026-08-24,United States,No,https://clinicaltrials.gov/study/NCT06037837
NCT06047379,"An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.",Phase 1/Phase 2,Recruiting,Interventional,"Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma",NEO212 Oral Capsule; Ipilimumab; Pembrolizumab; Nivolumab; Regorafenib; Carboplatin; Paclitaxel; FOLFIRI Protocol; Bevacizumab,,"Neonc Technologies, Inc.",,134,2023-11-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT06047379
NCT06058377,Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer,Phase 3,Recruiting,Interventional,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma,Biospecimen Collection; Cyclophosphamide; Doxorubicin; Durvalumab; Genetic Testing; Mammography; Paclitaxel; Quality-of-Life Assessment,,National Cancer Institute (NCI),,3680,2023-11-27,2026-05-31,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06058377
NCT06131840,An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Carcinoma",PF-08046050; bevacizumab; 5-Fluorouracil (5-FU); Oxaliplatin; Leucovorin (LV),,"Seagen, a wholly owned subsidiary of Pfizer",Sanofi,914,2023-11-20,2030-09-12,Canada; France; Netherlands; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06131840
NCT06138808,Prognostic Value of the 5-SENSE Score to Predict Focality of the Seizure-onset Zone as Assessed by Stereo-electroencephalography - a Prospective Multicenter Validation Study,,Enrolling by invitation,Observational,Epilepsy Intractable,Stereoelectroencephalography (SEEG),,Duke University,Christian Doppler University Hospital,400,2024-01-09,2025-11-05,Australia; Austria; Canada; Czechia; Denmark; France; Germany; Japan; Romania; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06138808
NCT06176261,DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs,Phase 2,Recruiting,Interventional,Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer,Datopotamab Deruxtecan,,"Sarah Sammons, MD",Daiichi Sankyo,58,2024-01-08,2029-01-01,United States,No,https://clinicaltrials.gov/study/NCT06176261
NCT06224673,Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer,Phase 2,Not yet recruiting,Interventional,HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma,ARX788; Computed Tomography (CT); Biospecimen Collection; Amiloride,,"Laura Huppert, MD, BA","Ambrx, Inc.",36,2026-01-15,2029-03-31,United States,No,https://clinicaltrials.gov/study/NCT06224673
NCT06241456,"A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor,FT825; Fludarabine; Cyclophosphamide; Bendamustine; Docetaxel; Cisplatin; Cetuximab,,Fate Therapeutics,,351,2024-01-05,2044-05-01,United States,No,https://clinicaltrials.gov/study/NCT06241456
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06270706,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor,PLN-101095; Pembrolizumab,,"Pliant Therapeutics, Inc.",,77,2023-08-30,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06270706
NCT06356311,"A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)",Phase 3,Recruiting,Interventional,Gastroesophageal Cancer,Sacituzumab tirumotecan; Trifluridine-Tipiracil; Irinotecan; Paclitaxel; Docetaxel; Rescue medication; Supportive care measures,,Merck Sharp & Dohme LLC,,450,2024-05-03,2027-05-06,Belgium; Brazil; Canada; Chile; China; Colombia; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; Malaysia; Mexico; Peru; Poland; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06356311
NCT06362369,"A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations,Alintegimod; Ipilimumab; Nivolumab,,"7 Hills Pharma, LLC",,126,2024-08-23,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT06362369
NCT06502171,A Phase 1/1b/2 Study of Cabozantinib in Combination With Selumetinib for Plexiform Neurofibroma in Adults and Adolescents With Neurofibromatosis Type 1,Phase 1,Not yet recruiting,Interventional,Neurofibromatosis 1; Plexiform Neurofibroma,Cabozantinib Oral Tablet; Selumetinib Oral Capsule,,"Girish Dhall, MD",Children's Hospital of Philadelphia; Indiana University; United States Department of Defense,30,2026-03-01,2034-03-01,United States,No,https://clinicaltrials.gov/study/NCT06502171
NCT06525766,"Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer",Phase 2,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen-receptor-positive Breast Cancer; Metastatic HER2-Negative Breast Carcinoma; Metastatic Breast Cancer,Biospecimen Collection; Bone Scan; Capecitabine; Computed Tomography; Magnetic Resonance Imaging; Questionnaire Administration,,Mayo Clinic,,35,2025-10-01,2030-10-15,United States,No,https://clinicaltrials.gov/study/NCT06525766
NCT06552260,A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma,Early Phase 1,Recruiting,Interventional,Glioblastoma; Recurrent Glioblastoma; Brain Tumor,Troriluzole,,Ugonma Chukwueke,"National Institutes of Health (NIH); Biohaven Pharmaceuticals, Inc.",27,2025-02-19,2027-08-01,United States,No,https://clinicaltrials.gov/study/NCT06552260
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06590454,Therapeutic Intervention to Reverse Gastric Precancer,Phase 2,Recruiting,Interventional,Gastric Intestinal Metaplasia; Gastric Precancer,Pyrvinium; Placebo,,Katherine Garman,,32,2025-12-01,2026-10-01,United States,No,https://clinicaltrials.gov/study/NCT06590454
NCT06590857,"Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1).",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Breast Cancer; HER2-negative Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,RYZ101,,"RayzeBio, Inc.",,124,2024-07-19,2033-01-05,United States,No,https://clinicaltrials.gov/study/NCT06590857
NCT06623201,Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas,Phase 1,Recruiting,Interventional,Basal Cell Carcinoma (BCC),aminolevulinic acid HCL (ALA); BLU-U device model 4170E,,Nathalie Zeitouni,,20,2024-10-07,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT06623201
NCT06625515,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients With Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Breast Cancer Recurrent; Colorectal Cancer Metastatic; Colon Cancer; Rectal Adenocarcinoma; Endometrial Cancer,ATX-559,,Accent Therapeutics,,100,2024-10-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT06625515
NCT06628310,"A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)",Phase 2,Recruiting,Interventional,Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma,Telisotuzumab Adizutecan; Budigalimab; Fluorouracil; Leucovorin; Oxaliplatin,,AbbVie,,180,2024-12-13,2030-10-05,Belgium; Canada; China; Germany; Israel; Japan; Puerto Rico; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06628310
NCT06678269,"A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer",Phase 1,Recruiting,Interventional,Metastatic Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Breast Cancer Metastatic; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Hormone-receptor-positive Breast Cancer,Abemaciclib; Radiation Therapy,,Memorial Sloan Kettering Cancer Center,Eli Lilly and Company,28,2024-11-15,2028-11-30,United States,No,https://clinicaltrials.gov/study/NCT06678269
NCT06686394,"HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Breast Neoplasms; Breast Cancer,Patritumab deruxtecan; Trastuzumab; Trastuzumab Biosimilar; Pertuzumab; Tucatinib,,Merck Sharp & Dohme LLC,Daiichi Sankyo,81,2025-02-26,2030-04-18,Canada; Israel; Japan; South Korea; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06686394
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06710847,"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)",Phase 1/Phase 2,Recruiting,Interventional,"Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer",GSK4418959; PD-1 inhibitor,,GlaxoSmithKline,IDEAYA Biosciences,73,2024-12-13,2028-06-16,Australia; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06710847
NCT06730750,"A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,BMS-986490; Bevacizumab,,Bristol-Myers Squibb,,360,2025-02-12,2029-12-09,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06730750
NCT06824363,"Proof of Principle Study Evaluating Single Dose Dual Immune Checkpoint Inhibitors to Increase Intra-tumoral T Cells in Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinomas With ARID1A Mutations: ESR-22-22082",Early Phase 1,Not yet recruiting,Interventional,"Solid Tumor, Adult; Malignant Solid Tumor; Stomach Adenocarcinoma; Esophageal Adenocarcinoma",Tremelimumab; Durvalumab,,"University of California, Irvine",,34,2025-11-05,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT06824363
NCT06828588,Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy,Early Phase 1,Not yet recruiting,Interventional,"Locally Advanced Cancer; Metastatic Cancer; HER2; HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma; HER 2 Low-expressing Breast Cancer",ABY-025 Loading Dose; [68Ga]Ga-ABY-025,,Vanderbilt-Ingram Cancer Center,,30,2025-11-05,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT06828588
NCT06840483,Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer,Phase 2,Recruiting,Interventional,Breast Cancer,Zelenectide pevedotin (BT8009),,BicycleTx Limited,,66,2025-03-03,2028-12-30,Australia; Belgium; France; Italy; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06840483
NCT06844669,HER2HEART-US: Primary Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy: a Pilot 2x2 Factorial Randomized Controlled Trial,Phase 2,Recruiting,Interventional,HER2-positive Breast Cancer; HER2+ Breast Cancer,Carvedilol; Empagliflozin,,Washington University School of Medicine,,40,2025-04-16,2026-05-31,United States,No,https://clinicaltrials.gov/study/NCT06844669
